881
Participants
Start Date
June 14, 2012
Primary Completion Date
February 4, 2015
Study Completion Date
May 15, 2015
Peginterferon Lambda-1a
Syringes, subcutaneous (SC), 180μg, Once weekly, 24 or 48 weeks depending on response
Peginterferon Alfa-2a
Syringes, SC, 180μg, Once weekly, 24 or 48 weeks depending on response
Ribavirin
Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 24 or 48 weeks depending on response
Telaprevir
Tablets, Oral, 750 mg, three times a day, 12 weeks only
Local Institution, Brussels
Local Institution, Edegem
Local Institution, Leuven
Local Institution, Liège
Local Institution, Linz
Local Institution, Basel
Local Institution, Graz
Local Institution, Zurich
Local Institution, Torino
Local Institution, Berlin
Local Institution, A Coruña
Local Institution, Santiago de Compostela
Local Institution, Nazareth
Local Institution, Botucatu
Local Institution, Donostia / San Sebastian
Local Institution, Milan
Local Institution, Hamburg
Local Institution, Rio de Janeiro
Mercy Medical Center, Baltimore
Metropolitan Research, Annandale
Digestive And Liver Disease Specialists, Norfolk
Bon Secours St. Mary'S Hospital Of Richmond, Inc., Newport News
Local Institution, Bergamo
Carolinas Medical Center, Charlotte
Gastrointestinal Specialists Of Georgia Pc, Marietta
Local Institution, Hanover
Local Institution, Toulouse
Local Institution, Haifa
Orlando Va Medical Center, Orlando
Orlando Clinical Research Center, Orlando
Infectious Disease Research Institute, Inc., Tampa
Local Institution, Haifa
Local Institution, Rennes
Birmingham Gastroenterology Associates, P.C., Birmingham
The Kirklin Clinic, Birmingham
The University Of Alabama Of Birmingham, Birmingham
Gastro One, Germantown
Local Institution, Salvador
Local Institution, Seville
Local Institution, Seville
Local Institution, Orléans
Local Institution, Essen
Local Institution, Münster
Local Institution, Ramat Gan
Local Institution, Cisanello (pisa)
Local Institution, Frankfurt
Saint Louis University, St Louis
Saint Luke'S Transplant Specialists, Kansas City
Options Health Research, Llc, Tulsa
Healthcare Research Consultants, Tulsa
Texas Clinical Research Institute, Arlington
Local Institution, Rouen
Alamo Medical Research, San Antonio
Brooke Army Medical Center, Fort Sam Houston
Local Institution, Curitiba
Clinical Research Centers Of America, Murray
Local Institution, Poitiers
Local Institution, Ulm
Local Institution, Porto Alegre
Cedars Sinai Medical Center, Los Angeles
Va Greater Los Angeles Healthcare System, Los Angeles
South Bay Ge Medical Group, Torrance
Va Long Beach Healthcare System, Long Beach
Local Institution, Jerusalem
Anaheim Clinical Trials Llc, Anaheim
Sc Clinical Research, Inc., Garden Grove
University Of California, San Francisco/Sf General Hospital, San Francisco
Local Institution, Villejuif
Local Institution, Moscow
Local Institution, Moscow
Local Institution, Moscow
Local Institution, Moscow
Local Institution, Moscow
Local Institution, Moscow
Local Institution, Moscow
Local Institution, Saint Petersburg
Local Institution, Saint Petersburg
Local Institution, Stavropol
Local Institution, Kazan'
Local Institution, Salvador
Local Institution, Curitiba
Local Institution, Porto Alegre
Local Institution, Botucatu
Local Institution, Rio de Janeiro
Local Institution, São Paulo
Local Institution, São Paulo
University Of Calgary, Calgary
Liver And Intestinal Research Centre (Lair), Vancouver
Gastrointestinal Research Institute (G.I.R.I.), Vancouver
Percuro Clinical Research Ltd, Victoria
Toronto General Hospital, Toronto
Hopital Maisonneuve-Rosemont, Montreal
Local Institution, Hradec Králové
Local Institution, Prague
Local Institution, Prague
Local Institution, Roma
Local Institution, Bialystok
Local Institution, Kielce
Local Institution, Mysłowice
Local Institution, Racibórz
Local Institution, Wroclaw
Local Institution, Łańcut
Local Institution, Alicante
Local Institution, Birmingham
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY